Have your say on PBS listings for IBD medications – May/June 2020
The Pharmaceutical Benefits Advisory Committee (PBAC) is seeking consumer feedback on submissions relating to some IBD medications on the Pharmaceutical Benefits Scheme (PBS).
You may like to provide feedback if you have experience taking Adalimumab biosimilar – Hadlima®:
Change to listing – (Minor Submission)
Form(s) & strength(s):
Injection 40 mg in 0.8 mL pre-filled syringe
Injection 40 mg in 0.8 mL single dose autoinjector
Merck, Sharp & Dohme (Australia) Pty Ltd
Drug Type & Use:
Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Juvenile idiopathic arthritis; Severe crohn’s disease; Refractory fistulising crohn’s disease; moderate to severe hidradenitis suppurativa
Listing requested by Sponsor / Purpose of Submission:
To request an extension to the currently approved PBS listing of Hadlima to include all indications for which Humira is currently PBS listed.
If you would like to provide information on the impact of proposed changes you can email [email protected] and CCA will forward your comments grouped with those of others to PBAC.
The closing date for comments to CCA is 8 June 2020.